Solid tumour immunotherapies often fail or have limited benefit because target antigens are heterogeneous, downregulated, lost, or expressed on normal tissues leading to off-tumour toxicity. To address these antigen-related obstacles, the authors propose a strategy termed tumour-targeted antigen programming (TRAP). TRAP intentionally and selectively reintroduces a clinically validated antigen into tumour cells so that existing therapeutic antibodies can be repurposed against solid tumours that do not natively express the antigen.
The report focuses on ectopic expression of CD20, an established antigen in B-cell malignancies, to redirect the anti-CD20 monoclonal antibody rituximab toward solid tumours. The rationale is that using a validated antigen–antibody pair may accelerate translational potential by leveraging known antibody pharmacology and mechanisms of action while avoiding problems of native antigen escape or absence.
To achieve tumour-selective ectopic antigen expression, the investigators used adeno-associated virus (AAV) vectors to deliver a CD20 transgene. Expression was placed under the control of an NF-κB-specific promoter intended to restrict transgene activation to tumour cells, where NF-κB signaling is typically elevated compared with normal tissues. The source reports that this approach produced selective CD20 expression confined to tumour tissue in the models studied.
The use of an inducible or tumour-responsive promoter is central to TRAP’s safety and specificity concept: by coupling antigen expression to a tumour-associated transcriptional program, ectopic antigen display should be minimized in nonmalignant cells, reducing the risk of off-tumour antibody-mediated toxicity.
Following TRAP-mediated expression of CD20 on tumour cells, the authors treated tumours with rituximab. The abstract reports that rituximab engagement invoked multiple antibody-dependent effector mechanisms, including natural killer cell–mediated antibody-dependent cellular cytotoxicity (ADCC) and macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Complement-dependent cytotoxicity (CDC) is also noted among the effector pathways engaged.
By recruiting several distinct immune effector arms, the TRAP–rituximab combination aims to produce robust antitumour activity even in contexts where a single effector mechanism might be insufficient. The source emphasizes that repurposing an approved antibody enables leveraging its established effector functions in a new tumour indication.
The study authenticated TRAP across a range of preclinical systems. According to the source, the experimental validation included:
Across these models, the authors report that TRAP achieved tumour-selective CD20 expression and that rituximab treatment produced antitumour effects. The inclusion of both human-derived organoids and mouse in vivo systems supports evaluation of both mechanism and therapeutic activity in contexts with differing immune components.
The source states that TRAP demonstrated high tumour-cell specificity in vitro and in vivo, and that this specificity translated into strong therapeutic efficacy in the tested models. By creating ectopic expression of a validated antigen, TRAP is presented as a new modality of immune-redirection therapy: it repurposes both a clinically validated antigen (CD20) and a licensed therapeutic antibody (rituximab) to address solid tumours that otherwise lack suitable target antigens.
This strategy aims to overcome antigen heterogeneity and loss that limit existing antigen-dependent immunotherapies and to reduce off-tumour toxicity by restricting antigen expression to tumour tissue through an NF-κB-responsive promoter. The reported activation of ADCC, ADCP, and CDC by rituximab suggests a multi-mechanistic antitumour response.
The PubMed abstract and accompanying entry summarize the conceptual framework, methods, model systems, and qualitative outcomes. However, the source record provided does not include quantitative efficacy metrics, dosing details, safety or toxicity data, duration of responses, or detailed methods and statistical analyses. Those specifics are not reported in the provided abstract and would need to be consulted in the full article for comprehensive evaluation and interpretation.